![Marek Poszepczynski](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Marek Poszepczynski
Plus aucun poste en cours
Profil
Marek Poszepczynski worked as a Licensing Director at Biovitrum AB from 2002 to 2008.
He then worked as a Vice President of Business Development at Karolinska Development AB from 2008 to 2010.
From 2010 to 2012, he was a Lead Equity Analyst at Svenska Handelsbanken AB.
He also worked as a Vice President of Business Development at Axelar AB.
From 2012 to 2017, he was a Director of Business Development at Calliditas Therapeutics AB.
Prior to his business career, he graduated from the Royal Institute of Technology.
Anciens postes connus de Marek Poszepczynski
Sociétés | Poste | Fin |
---|---|---|
CALLIDITAS THERAPEUTICS AB | Corporate Officer/Principal | 01/03/2017 |
SVENSKA HANDELSBANKEN AB | Corporate Officer/Principal | 01/01/2012 |
KAROLINSKA DEVELOPMENT AB | Corporate Officer/Principal | 01/01/2010 |
Biovitrum AB
![]() Biovitrum AB Miscellaneous Commercial ServicesCommercial Services Biovitrum AB develops and sells specialist pharmaceuticals that improve people's lives. The company's business goal is to create a pharmaceutical company with long-term profitability through the international launch and sale of in-house developed products. Research expertise and capabilities are focused on development and production of biotechnology therapeutics within the prioritized areas of hemophilia, inflammation/autoimmune diseases, cancer supportive care and malabsorption. The company was founded in January 2001 and is headquartered in Stockholm, Sweden. | Corporate Officer/Principal | 01/01/2008 |
SV Health Investors LLP
![]() SV Health Investors LLP Investment ManagersFinance SV Health Investors LLP (SV Health Investors) is a venture capital firm founded in 1994 by Peter McPartland. The firm is headquartered in London. | Private Equity Investor | - |
Formation de Marek Poszepczynski
Royal Institute of Technology | Graduate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 3 |
---|---|
CALLIDITAS THERAPEUTICS AB | Health Technology |
KAROLINSKA DEVELOPMENT AB | Finance |
SVENSKA HANDELSBANKEN AB | Finance |
Entreprise privées | 4 |
---|---|
Axelar AB
![]() Axelar AB BiotechnologyHealth Technology Axelar AB operates as a biotechnology company. It aims to develop novel efficacious anti-cancer treatments. The company was founded by Erik Gustav Magnus Axelson and Lars Olov Larsson in 2003 and is headquartered in Solna, Sweden. | Health Technology |
Svenska Handelsbanken AB (Broker)
![]() Svenska Handelsbanken AB (Broker) Investment Banks/BrokersFinance Svenska Handelsbanken AB (Broker) (Handelsbanken-Broker) is the broker/dealer division of Svenska Handelsbanken AB (STO: SHB-A; OTCMKTS: SVNLY) in Sweden. Headquartered in Stockholm, Handelsbanken-Broker was founded in 1871 and provides trading services to large corporates. The firm trades in equities, money market instruments, currencies, commodities and derivatives. | Finance |
Biovitrum AB
![]() Biovitrum AB Miscellaneous Commercial ServicesCommercial Services Biovitrum AB develops and sells specialist pharmaceuticals that improve people's lives. The company's business goal is to create a pharmaceutical company with long-term profitability through the international launch and sale of in-house developed products. Research expertise and capabilities are focused on development and production of biotechnology therapeutics within the prioritized areas of hemophilia, inflammation/autoimmune diseases, cancer supportive care and malabsorption. The company was founded in January 2001 and is headquartered in Stockholm, Sweden. | Commercial Services |
SV Health Investors LLP
![]() SV Health Investors LLP Investment ManagersFinance SV Health Investors LLP (SV Health Investors) is a venture capital firm founded in 1994 by Peter McPartland. The firm is headquartered in London. | Finance |